The available randomized data indicates that long-term P2Y12 inhibitor therapy may be a more appropriate choice than aspirin monotherapy for secondary prevention in patients with CAD [5,6,49,50,56,69]. This evidence concerns the gene P2RY12 and coronary artery disorder.